Why I might buy Smith & Nephew shares after a 6% price surge

A Q3 update sent the Smith & Nephew plc (LSE: SN) share price flying, but I believe there’s more to come.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Buy what you know,” goes the old investing mantra. And I think I know Smith & Nephew (LSE: SN), which makes surgical implants, reasonably well. I’ve worked in that business in the past, and I know how widely used and well regarded are its products — they really are among the best.

I’m currently eyeing up possibilities for my next SIPP investment, and the 6% share price spike at Smith & Nephew on Thursday drew my attention. It’s a response to the latest trading update, which reported a 3% rise in third-quarter underlying revenue.

Chief executive Namal Nawana cited US and Emerging Markets growth as driving the overall improvement, with underlying US revenue up 4% and Emerging Markets revenue surging by 10%.

That sounds like really good news, as uncertain US markets have been contributing to the company’s share price volatility all year.

New markets

The firm also reported “strong growth in Reconstruction, Sports Medicine Joint Repair and Advanced Wound Devices,” which are potentially lucrative markets.

Smith & Nephew does appear to be doing well at refocusing the way it does business, with Nawana adding: “These results were achieved while successfully redesigning how we will run the company. There is still more to do, and I am pleased with the pace of progress and engagement across the organisation.”

Smith & Nephew’s dividend yields aren’t great, with forecasts a little above the 2% mark. But they should be well covered by earnings and are progressive — and a sustainable and rising divided can be better than a big yield today.

I want to see how well the new strategy progresses, but Smith & Nephew is definitely on my shortlist.

Growth share dip

I’ve also had my eye on NMC Health (LSE: NMC) for some time, though the share price chart has started to look scarily like some of the growth bubbles we’ve seen in the past few years. And I’ve been fearing it might go pop.

But from a peak of 4,376p in August, the price has shed 20% to drop to 3,508p as I write, so are we looking at an unexpected buying opportunity? 

First-half figures in August were impressive, but actually proved to be pivotal for the share price, which went into a two-month slide. Were investors hoping for even better results? It’s hard to tell, but it’s quite common for growth investors to be expecting spectacular results when all they actually get is seriously good ones — and they’ll often run for the hills when that happens.

Upgraded guidance

But NMC revised its guidance upwards a week ago, and that could well have given fresh life to the share price and we’re seeing it moving upwards again. After a strong first half, the firm now expects a 24% rise in revenue for the full year, and has lifted EBITDA guidance from $465m to $480m.

The shares are currently priced at 25 times forecast 2019 earnings per share, which definitely requires solid growth to justify. But predictions suggest 30% EPS rises this year and next, and we’re looking at an attractive PEG ratio of only 0.8.

I still see NMC as a strong growth candidate, with a likelihood of turning into a big-dividend cash cow in the future.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be considered so you should consider taking independent financial advice.

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has recommended NMC Health. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Modern suburban family houses with car on driveway
Investing Articles

Should I snap up Taylor Wimpey shares at £1.30?

With the Taylor Wimpey share price down by almost 30% this year, should I snap up some shares while it's…

Read more »

Young female analyst working at her desk in the office
Investing Articles

How I’m finding shares to buy now – and keep for a decade

Our writer has been looking for shares to buy using an approach that looks both at long-term profit prospects and…

Read more »

Bearded man writing on notepad in front of computer
Investing Articles

What’s happening to the Petrofac (PFC) share price?

The Petrofac (LON:PFC) share price has had a seriously erratic year so far. I take a look at the latest…

Read more »

Young black woman in a wheelchair working online from home
Investing Articles

The Aviva share price is flying! Should I buy this 7% yield?

Despite recent gains, Roland Head thinks the Aviva share price could still be too cheap.

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

Here’s 1 passive income opportunity not to be missed!

This Fool details a passive income opportunity that could bolster his holdings, and the shares trading at cheap levels too.

Read more »

Young brown woman delighted with what she sees on her screen
Investing Articles

The Legal & General share price is dirt-cheap with a juicy dividend yield!

Jabran Khan takes a closer look at the Legal & General share price which looks like an opportunity to boost…

Read more »

Playful senior couple in aprons dancing and smiling while preparing healthy dinner at home
Investing Articles

If I’d invested £1,000 in this top lithium stock 5 years ago, here’s how much I’d have now!

This lithium stock has gone from strength to strength over the past year. But has it flown too high, or…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

A growth stock with a price-to-earnings ratio of just 9.7! Should I buy Yalla?

I'm generally not too keen on investing in dollar-demonated stocks at the moment. But Yalla, with its low price-to-earnings ratio,…

Read more »